Is FHLC a good investment?

Fidelity MSCI Health Care Index ETF (FHLC) is a healthcare and biotech ETF. As of September 11, 2026, ETF Copilot scores FHLC 5.5 out of 10 — highest on Risk (8.3), lowest on Return (3.5). It trades at 30.0 times earnings, against its own median of 24.8. Its ten largest holdings are 52% of the fund.

Updated September 11, 2026

How is FHLC rated? ETF Copilot scores Fidelity MSCI Health Care Index ETF (FHLC) 5.5 out of 10

As of September 11, 2026, ETF Copilot scores Fidelity MSCI Health Care Index ETF (FHLC) 5.5 out of 10 overall.

ETF Copilot scores (0–10 scale, higher is better):

Overall: 5.5 / 10
Growth: 7.7 / 10
Valuation: 3.8 / 10
Risk: 8.3 / 10
Quality: 3.9 / 10
Return: 3.5 / 10

What is FHLC's expense ratio? 0.08% a year

As of September 11, 2026, FHLC charges 0.08% a year, yields 1.55% and holds $3.5B in assets across 331 positions.

Fidelity MSCI Health Care Index ETF (FHLC) — cost, income and size
Measure	FHLC
Expense ratio	0.08%
Dividend yield	1.55%
Assets under management	$3.5B
Holdings	331

Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.

What stands out in FHLC's data

U.S. healthcare companies, tracked through a broad index.

Trades at a richer price than its own history or the typical peer — you pay more for each dollar of earnings.

Trailing P/E multiple of 30.0x sits above the category median of 27.2x and the fund's own 24.7x historical median. Return on equity of 29.3% is a bright spot.

A broad sector position that keeps healthcare exposure without tilting toward any one subspecialty.

Why did FHLC move this week? It fell 4.4% in the week to September 11, 2026 — Eli Lilly and Amgen drove it

FHLC fell 4.4% in the week to September 11, 2026. The holdings that moved it most were Eli Lilly (−3.8%), Amgen (−15.0%) and Johnson & Johnson (−4.6%); Roivant Sciences (+18.6%) pushed the other way.

Is FHLC expensive right now? It trades at 30.0 times earnings, against its own median of 24.8

As of September 11, 2026, FHLC is more expensive than 89% of its own 114 monthly readings since 2017 — 101 of those months were cheaper than today.

Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.

What's inside FHLC?

What's inside FHLC: Size (Large 82%, Mid 13%, Small 5%); Geography (International 3%, US 97%); Tech 0.1%; AI 0.4%.

What are FHLC's top holdings? The ten largest are 52% of the fund

Eli Lilly, Johnson & Johnson, Abbvie, Merck, UnitedHealth, Thermo Fisher Scientific, Amgen, Abbott Laboratories, Gilead Sciences and Pfizer are FHLC's largest holdings, in that order.

More concentrated than 60% of Healthcare & Biotech ETFs.

Half of FHLC's weight sits in its 10 largest positions, and once those weights are taken into account it behaves like 24 equally weighted holdings.

Cite this

ETF Copilot, “Fidelity MSCI Health Care Index ETF (FHLC) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/fhlc